ISG15 inhibits IFN- α -Resistant liver cancer cell growth

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Wan, Xin Xing ^a   Chen, Han Chun ^a   Khan, Md Asaduzzaman ^a   Xu, Ai Hua ^a   Yang, Fu Lan ^a   Zhang, Yun Yi ^a   Zhang, Dian Zheng ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ISG15 PROTEIN; PROTEIN P21; PROTEIN P53; UBIQUITIN; UNCLASSIFIED DRUG; CYTOKINE; ISG15 PROTEIN, HUMAN; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL STRAIN HEPG2; CELL SURVIVAL; DNA DAMAGE; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CANCER CELL GROWTH; PROTEIN EXPRESSION; STRESS; UBIQUITINATION; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; UPREGULATION; CARCINOMA, HEPATOCELLULAR; HEPG2 CELL LINE; LIVER NEOPLASMS;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS; UP-REGULATION;

EID: 84884225922     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/570909     Document Type: Article

References (29)

1. Gish R. G., Hepatocellular carcinoma: overcoming challenges in disease management. Clinical Gastroenterology and Hepatology 2006 4 3 252 261 2-s2.0-33644778515 10.1016/j.cgh.2006.01.001
2. Worns M. A., Galle P. R., Future perspectives in hepatocellular carcinoma. Digestive and Liver Disease 2010 42 supplement 3 S302 S309
3. Ihle J. N., The Janus protein tyrosine kinase family and its role in cytokine signaling. Advances in Immunology 1995 60 1 35 2-s2.0-0028786276
4. Hervas-Stubbs S., Perez-Gracia J. L., Rouzaut A., Sanmamed M. F., Le Bon A., Melero I., Direct effects of type I interferons on cells of the immune system. Clinical Cancer Research 2011 17 9 2619 2627 2-s2.0-79955509835 10.1158/1078-0432.CCR-10-1114
5. Ghislain J. J., Wong T., Nguyen M., Fish E. N., The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes. Journal of Interferon and Cytokine Research 2001 21 6 379 388 2-s2.0-0034919802 10.1089/107999001750277853
6. Knigth E. Jr., Fahey D., Cordova B., Hillman M., Kutny R., Reich N., Blomstrom D., A 15-kDa interferon-induced protein is derived by COOH-terminal processing of a 17-kDa precursor. The Journal of Biological Chemistry 1988 263 10 4520 4522 2-s2.0-0023876086
7. Pickart C. M., Fushman D., Polyubiquitin chains: polymeric protein signals. Current Opinion in Chemical Biology 2004 8 6 610 616 2-s2.0-8844237615 10.1016/j.cbpa.2004.09.009
8. Hershko A., Ciechanover A., The ubiquitin system. Annual Review of Biochemistry 1998 67 425 479 2-s2.0-0031657807 10.1146/annurev.biochem.67.1.425
9. Yuan W., Krug R. M., Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO Journal 2001 20 3 362 371 2-s2.0-0035253852 10.1093/emboj/20.3.362
10. Zou W., Zhang D.-E., The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. The Journal of Biological Chemistry 2006 281 7 3989 3994 2-s2.0-33645217490 10.1074/jbc.M510787200
11. Zhao C., Beaudenon S. L., Kelley M. L., Waddell M. B., Yuan W., Schulman B. A., Huibregtse J. M., Krug R. M., The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN- α / β -induced ubiquitin-like protein. Proceedings of the National Academy of Sciences of the United States of America 2004 101 20 7578 7582 2-s2.0-2442717751 10.1073/pnas.0402528101
12. Desai S. D., Wood L. M., Tsai Y.-C., Hsieh T.-S., Marks J. R., Scott G. L., Giovanella B. C., Liu L. F., ISG15 as a novel tumor biomarker for drug sensitivity. Molecular Cancer Therapeutics 2008 7 6 1430 1439 2-s2.0-49849102784 10.1158/1535-7163.MCT-07-2345
13. Vollmer C. M., Ribas A., Butterfield L. H., Dissette V. B., Andrews K. J., Eilber F. C., Montejo L. D., Chen A. Y., Hu B., Glaspy J. A., McBride W. H., Economou J. S., p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Research 1999 59 17 4369 4374 2-s2.0-0033199168
14. Chène P., Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Reviews Cancer 2003 3 2 102 109 2-s2.0-0037317840 10.1038/nrc991
15. Singhal A., Jayaraman M., Dhanasekaran D. N., Kohli V., Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012 82 2 116 140 2-s2.0-84859433790 10.1016/j.critrevonc.2011.05.005
16. Okumura A., Pitha P. M., Harty R. N., ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proceedings of the National Academy of Sciences of the United States of America 2008 105 10 3974 3979 2-s2.0-41649084195 10.1073/pnas.0710629105
17. Liu M., Xiao-Ling X.-L., Hassel B. A., Proteasomes modulate conjugation to the ubiquitin-like protein, ISG15. The Journal of Biological Chemistry 2003 278 3 1594 1602 2-s2.0-0037449715 10.1074/jbc.M208123200
18. Murphy D., Detjen K. M., Welzel M., Wiedenmann B., Rosewicz S., Interferon- α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001 33 2 346 356 2-s2.0-0035146416 10.1053/jhep.2001.21749
19. Wu W.-Z., Sun H.-C., Gao Y.-Q., Li Y., Wang L., Zhou K., Liu K.-D., Iliakis G., Tang Z.-Y., Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 2004 67 5-6 428 440 2-s2.0-13844311013
20. Damdinsuren B., Nagano H., Wada H., Noda T., Natsag J., Marubashi S., Miyamoto A., Takeda Y., Umeshita K., Doki Y., Dono K., Monden M., Interferon alpha receptors are important for antiproliferative effect of interferon- α against human hepatocellular carcinoma cells. Hepatology Research 2007 37 1 77 83 2-s2.0-33947159315 10.1111/j.1872-034X.2007.00007.x
21. Wong N., Chan K. Y.-Y., Macgregor P. F., Lai P. B.-S., Squire J. A., Beheshti B., Albert M., Leung T. W.-T., Transcriptional profiling identifies gene expression changes associated with IFN- α tolerance in hepatitis C-related hepatocellular carcinoma cells. Clinical Cancer Research 2005 11 3 1319 1326 2-s2.0-12944284583
22. Noda T., Nagano H., Takemasa I., Yoshioka S., Murakami M., Wada H., Kobayashi S., Marubashi S., Takeda Y., Dono K., Umeshita K., Matsuura N., Matsubara K., Doki Y., Mori M., Monden M., Activation of Wnt Β -catenin signalling pathway induces chemoresistance to interferon- α 5-fluorouracil combination therapy for hepatocellular carcinoma. British Journal of Cancer 2009 100 10 1647 1658 2-s2.0-67349198077 10.1038/sj.bjc.6605064
23. Yim H. Y., Yang Y., Lim J. S., Lee M. S., Zhang D. E., Kim K. I., The mitochondrial pathway and reactive oxygen species are critical contributors to interferon- α / β -mediated apoptosis in Ubp43-deficient hematopoietic cells. Biochemical and Biophysical Research Communications 2012 423 436 440
24. Catic A., Fiebiger E., Korbel G. A., Blom D., Galardy P. J., Ploegh H. L., Screen for ISG15-crossreactive deubiquitinases. PLoS ONE 2007 2 7, article e679 2-s2.0-39849091629 10.1371/journal.pone.0000679
25. Chau V., Tobias J. W., Bachmair A., Marriott D., Ecker D. J., Gonda D. K., Varshavsky A., A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989 243 4898 1576 1583 2-s2.0-0024514688
26. Sigismund S., Polo S., Di Fiore P. P., Signaling through monoubiquitination. Current Topics in Microbiology and Immunology 2004 286 149 185 2-s2.0-3242685293
27. Michael D., Oren M., The p53-Mdm2 module and the ubiquitin system. Seminars in Cancer Biology 2003 13 1 49 58 2-s2.0-0037329056 10.1016/S1044-579X(02)00099-8
28. Brazhnik P., Kohn K. W., HAUSP-regulated switch from auto- to p53 ubiquitination by Mdm2 (in silico discovery). Mathematical Biosciences 2007 210 1 60 77 2-s2.0-35248821834 10.1016/j.mbs.2007.05.005
29. Yadav V., Sultana S., Yadav J., Saini N., Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53. PLoS One 2012 7 e47796